Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Nov 19;10:20237. doi: 10.1038/s41598-020-77281-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Effect of topical selective 11β-HSD1 inhibitor on oxazolone-evoked AD. (a) Gross photograph of control (n = 5), and Ox-induced female hairless (hr/hr) mice with topically applied vehicle (n = 7) and 11β-HSD1 inhibitor (n = 7) taken before sacrifice (at 26 days). (b) Eczema scores of Ox-induced mice treated with 11β-HSD1 inhibitor and vehicle at challenges 5–10. (c) TEWL and SC hydration in control and Ox-induced mice with vehicle and 11β-HSD1 inhibitor before sacrifice (at 26 days) (*p < 0.05, **p < 0.005). Data are presented as means ± standard deviation. HSD1 inh 11β-HSD1 inhibitor, Ox oxazolone, SC stratum corneum, TEWL transepidermal water loss.